Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1403717 | 0.85 | ALDH1A1 (0.53) | ALDH1A1HSD17B10HPGDMAOACA2 | |
| SCHEMBL31632669 | 0.83 | CA2 (0.50) | ALDH1A1HSD17B10HPGDCA2CAMK2A | |
| SCHEMBL12255202 | 0.80 | ALDH1A1 (0.50) | ALDH1A1HSD17B10MAOAMAOBCA2 | |
| SCHEMBL167520 | 0.80 | MAOA (0.45) | ALDH1A1HSD17B10MAOAMAOBCA2 | |
| SCHEMBL670933 | 0.78 | PKM (0.51) | ALDH1A1HSD17B10HPGDCA2CAMK2A | |
| SCHEMBL6403659 | 0.77 | CA2 (0.47) | ALDH1A1HSD17B10HPGDMAOACA2 | |
| SCHEMBL1017821 | 0.77 | HTT (0.51) | ALDH1A1MAOAMAOBCA2CA12 | |
| SCHEMBL11690462 | 0.77 | CA2 (0.52) | ALDH1A1HSD17B10HPGDCA2CAMK2A | |
| SCHEMBL11301284 | 0.77 | CA2 (0.52) | ALDH1A1HSD17B10HPGDCA2CAMK2A | |
| SCHEMBL13397872 | 0.77 | CA12 (0.61) | ALDH1A1HPGDMAOAMAOBCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109803956-B | Novel benzamide compound, process for producing the same, and acaricide | 日本欧爱特农业科技株式会社 | 2023-08-29 | — | — | CN | disclosed |
| EP-3484855-B1 | NOVEL BENZYLAMIDE COMPOUND, METHOD FOR PRODUCING THE SAME, AND MITICIDE | OAT AGRIO CO LTD (JP) | 2022-02-23 | — | — | EP | disclosed |
| US-11000037-B2 | Benzylamide compound, method for producing the same, and miticide | OAT AGRIO CO., LTD. (JP) | 2021-05-11 | — | — | US | disclosed |
| US-20190281824-A1 | NOVEL BENZYLAMIDE COMPOUND, METHOD FOR PRODUCING THE SAME, AND MITICIDE | OAT & IIL INDIA LABORATORIES PRIVATE LIMITED (IN) | 2019-09-19 | — | — | US | disclosed |
| CN-109803956-A | Novel benzamide compounds, preparation method and acaricide | 杀虫剂(印度)有限公司 | 2019-05-24 | — | — | CN | disclosed |
| WO-2012028100-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-03-08 | — | — | WO | disclosed |
| EP-2168962-A2 | PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS | Prosidion Limited (GB) | 2010-03-31 | — | — | EP | disclosed |
| EP-1594867-B1 | PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS | PROSIDION LTD (GB) | 2008-04-09 | — | — | EP | disclosed |
| US-7214681-B2 | Tri(cyclo) substituted amide compounds | PROSIDION LIMITED (GB) | 2007-05-08 | — | — | US | disclosed |
| EP-1594867-A2 | PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS | Prosidion Limited (GB) | 2005-11-16 | — | — | EP | disclosed |
| US-20040181067-A1 | Tri(cyclo) substituted amide compounds | OSI PHARMACEUTICALS, INC. | 2004-09-16 | — | — | US | disclosed |
| WO-2004072031-A2 | PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS | PROSIDION LIMITED (GB) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11000037-B2 | Benzylamide compound, method for producing the same, and miticide | CBR3, CBR1, BRD9 | ALDH1A1 2726/4885HSD17B10 1977/4885HPGD 2149/4885 |
| US-20040181067-A1 | Tri(cyclo) substituted amide compounds | GPR119, IAPP, SLC5A1 | ALDH1A1 1595/4885HSD17B10 531/4885HPGD 1237/4885 |
| US-20190281824-A1 | NOVEL BENZYLAMIDE COMPOUND, METHOD FOR PRODUCING THE SAME, AND MITICIDE | CBR3, CBR1, NOX5 | ALDH1A1 2574/4885HSD17B10 1925/4885HPGD 2161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.